Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials Authors: Muhammad Osama, Muhammad Haris Khan, Ammara Tahir, Amna Hussain, Ahmad Iftikhar, Aizaz Ali, Safeena Khan, Malak Bilal Hassan, Intikhab Alam, Zeeshan Khan, Abdullah Afridi, Mohammad Ebad Ur Rehman, Amna Gul, Pawan Kumar Thada Published: 2026 ABSTRACT AbstractBackgroundMultiple myeloma (MM) is the second most common hematologic malignancy worldwide. Recent therapeutic innovations, including the addition of daratumumab to standard regimens, have shown promising improvements in patient outcomes.ObjectivesThis study aims to compare the efficacy and safety of daratumumab-based quadruplet therapy regimens with standard triplet therapy regimens in newly diagnosed multiple myeloma (NDMM) patients.DesignSystematic review and meta-analysis of randomized controlled trials.Data sources and MethodsA comprehensive literature search was conducted on PubMed, Cochrane Library, Embase, and ClinicalTrials.gov from inception to April 2026. Primary outcomes were Progression-free survival (PFS) and Minimal residual disease (MRD) negativity. Subgroup analysis based on cytogenetic risk was performed. The statistical assessment was done using The Review Manager (RevMan, Version 5.4).ResultsOur meta-analysis included 7 RCTs, comprising 3 studies in transplant-eligible multiple myeloma (TE-MM) and 4 in transplant-ineligible multiple myeloma (TIE-MM) patients, containing 3,443 patients (1,759 in the daratumumab group and 1684 in the non-daratumumab group). The median age across studies ranged from approximately 59 to 76 years. Daratumumab-based therapy demonstrated significantly higher PFS (HR 0.50, 95%CI: 0.43- 0.58, p < 0.00001). The analysis showed statistically significant high MRD negativity with daratumumab based quadruplet therapy compared to non-Dara triplet arm (RR 1.99, 95%CI 1.59-2.50, P<0.00001). Subgroup analysis based on cytogenetic risk demonstrated significant improved PFS in standard-risk (HR 0.45) as well as high-risk (HR 0.67), whereas MRD negativity increased significantly only in standard-risk (RR 1.76) but not high-risk (RR 1.23). Daratumumab-based quadruplet therapy was associated with increased neutropenia (56.2% vs 40.3%), thrombocytopenia (40.7% vs 32.5%), and infections (33.1% vs 23.3%).ConclusionThe meta-analysis shows higher efficacy yet higher adverse events in Daratumumab-based quadruplet therapy for NDMM patients (TE, and TIE).Keywords: daratumumab, newly diagnosed multiple myeloma, progression-free survival Introduction Multiple myeloma (MM) is a plasma cell malignancy, distinguished by the clonal proliferation of plasma cells. 1 MM is the second most common hematologic malignancy worldwide and is associated with high mortality. 2 Despite significant advancement in patient survival over the past decades, MM treatment remains complex with a survival ranging from a few months to over 10 years. 3 Daratumumab is a fully humanized IgGκ monoclonal antibody targeting CD38 on MM cells. It received its first FDA approval on June 27, 2019, for use in newly diagnosed multiple myeloma patient’s ineligible for autologous stem cell transplant (ASCT), in combination with lenalidomide and dexamethasone. 4 Subsequently, on September 26, 2019, daratumumab was also approved for use in transplant-eligible patients, in combination with bortezomib, thalidomide, and dexamethasone. 5 Thus, daratumumab is now FDA-approved for frontline therapy in both transplant-eligible and transplant-ineligible NDMM populations. Recently The NCCN Guidelines Version 5.2026 recommended four-drug regimens, including anti-CD38 monoclonal antibody–based quadruplets, as preferred primary therapy options for eligible patients with newly diagnosed multiple myeloma. 6 Currently, quadruplet therapy regimens comprising an anti-CD 38 monoclonal antibody like daratumumab and Isatuximab are preferred, leading to a higher Minimal Residual Disease (MRD) negativity and deeper responses, translating into longer Progression-Free Survival (PFS). 7 It is often used as a combination with standard induction therapy in various trials such as GRIFFIN, CASSIOPEIA, ALCYONE, and MAIA 8 , The CASSIOPEIA trial showed that adding daratumumab to VTD significantly improved MRD negativity in transplant-eligible (TE) patients. In the ALCYONE trial, daratumumab combined with VMP led to superior progression-free survival (PFS) and overall survival (OS) in transplant-ineligible patients (TIE), though with more infections. These trials showed efficacy of quadruplet therapies in MM, but in majority of trials the efficacy was restricted to standard cytogenetic risk group and was not statistically significant in high cytogenetic risk group. There are certain studies showing efficacy even in high cytogenetic risk groups, such as Master trial showing that daratumumab based quadruplet therapy produced deep remission in high cytogenetic risk group, but still even this study mentioned worse performance by patient with ultra-high risk.9,10 Previous meta-analyses have evaluated daratumumab-based induction therapy or the addition of daratumumab to MM backbone regimens; however, many were limited by the number of available randomized trials, broader inclusion criteria, or lack of specific focus on daratumumab-based quadruplet therapy compared with non-daratumumab triplet regimens in NDMM. In addition, the certainty of evidence for efficacy and safety outcomes, particularly across cytogenetic-risk subgroups, has not been fully clarified. With the availability of newer randomized controlled trials, an updated and focused synthesis is needed. Therefore, this systematic review and meta-analysis of randomized controlled trials aimed to compare the efficacy and safety of daratumumab-based quadruplet therapy versus non-daratumumab-based triplet therapy in patients with newly diagnosed multiple myeloma. We further assessed whether treatment benefit differed according to cytogenetic-risk status and evaluated the certainty of evidence using the GRADE approach to support clinical decision-making. Methods Study Design and Protocol Registration This systematic review and meta-analysis adhere to the guidelines established by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 11 , and it is registered in PROSPERO (CRD42024584896). Literature search strategy A systematic literature search was conducted on PubMed, Embase, ClinicalTrials.gov, and Cochrane from inception to April 2026, using Medical Subject Headings (MeSH) and keywords for “Multiple Myeloma” and “daratumumab”. Bibliographies of all the included articles were also searched for relevant articles. The comprehensive search string is accessible in full and is available in a supplementary Table 1. Study selection and eligibility criteria We imported all the references retrieved by our search into Endnote v20 and the duplicates were removed. Two authors (MHK and AH) independently screened all the studies’ titles and abstracts and removed those that did not fulfill our inclusion criteria. The remaining articles were evaluated against the eligibility criteria by reviewing their full texts. Disagreements and conflicts were discussed with a third author (AT) and resolved. The eligibility criteria were: 1. Population: Patients with newly diagnosed multiple myeloma (NDMM), including both transplant-eligible (TE) and transplant-ineligible (TIE) populations. 2. Intervention: daratumumab-based quadruplet therapy regimens for induction 3. Comparator: non-daratumumab-based triplet therapy regimen for induction 4. Study Designs: randomized control trials. Data extraction and outcomes Data were extracted independently by two authors (MO and AA) into a pre-defined data collection form on Microsoft Excel. In case of any discrepancies, a third author (SK) was consulted. The data extracted from the included studies comprised of study characteristics (first author, publication year, study setting, study design, and sample size), patient characteristics (age, sex), treatment characteristics (Regimen, maintenance therapy, dose of daratumumab in cycle 1, route of administration) and outcomes (stringent complete response (sCR), progression-free survival (PFS), complete response (CR), complete response or better (≥ CR), overall response (ORR), MRD negative status regardless of response, MRD negativity with complete response or better, VGPR, VGPR or better, progressive disease, stable disease. Safety profile includes hematological Adverse events or toxicity like neutropenia, thrombocytopenia, anemia, and lymphopenia whereas non-hematological adverse events or toxicity include diarrhea, pneumonia, upper respiratory tract infection, constipation, peripheral sensory neuropathy, fatigue, any infusion-related reaction, pyrexia, peripheral edema, nausea, cough, asthenia, back pain, and second primary cancer. MRD negativity and progression-free survival were the two primary outcomes. Quality Assessment Two independent authors (IA and MBH) evaluated the risk of bias in the studies that were included, utilizing the Cochrane “risk of bias” tool (RoB 2.0) for RCTs 12 . Studies were classified as having a low bias, some concerns, or a high risk of bias based on the assessment of the randomization process, deviation from intended intervention, missing outcome data, outcome measurement, and reporting bias. We discussed and resolved any discrepancies in the bias assessment with another author (ZA). GARDE assessment was also used to look for the quality of evidence. Data Synthesis and Statistical Analysis The data analysis was conducted by using Review Manager (RevMan, Version 5.4; The Cochrane Collaboration, Copenhagen, Denmark) software. The risk ratios (RR) with 95% confidence intervals were determined for qualitative data. The Mantel Haenszel method with random effects model was employed to aggregate the RRs. The hazard ratios (HR) were aggregated for variables involving time like PFS. The chi-square Cochrane Q test was utilized to identify any notable variation in heterogeneity among the various trials and between subgroups. The I2 statistic was used to assess the heterogeneity between the included studies. Cochrane Handbook for Systematic Reviews of Interventions, section 10.10 was used to interpret the I2 values. 13 Publication bias was assessed based on funnel plots visualization. Subgroup analyses: Subgroup analyses of all efficacy outcomes were conducted based on the transplant eligibility: (TEMM vs TIEMM), and cytogenetic risk (standard vs high risk). Results Search results Initially, the literature search retrieved 3,109 articles. 353 duplicates were then removed, leaving 2,756 unique articles. After screening the titles and abstracts, 2,662 articles were excluded, leaving 94 studies for full-text screening against the eligibility criteria. Ultimately, 7 RCTs were included in this meta-analysis, included trials encompassed both transplant-eligible (TE) and transplant-ineligible (TIE) populations.6,14–19 The CASSIOPEIA trial (Phase III) evaluated daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTD) in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, demonstrating improved depth of response. The GRIFFIN trial (Phase II) assessed daratumumab with lenalidomide, bortezomib, and dexamethasone (D-RVD) in a similar transplant-eligible NDMM population, showing deeper responses and MRD negativity. PERSEUS (Phase III) further confirmed the benefit of D-RVD with subcutaneous daratumumab in transplant-eligible NDMM. ALCYONE (Phase III) focused on transplant-ineligible NDMM, showing that daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) significantly prolonged PFS. The AMaRC 03-16 trial (Phase II) investigated daratumumab with VMP in elderly or frail transplant-ineligible NDMM patients, supporting its feasibility and efficacy. Lastly, OCTANS (Phase III) evaluated daratumumab with VMP in transplant-ineligible NDMM. The CEPHEUS trial (Phase III) evaluated daratumumab plus bortezomib, lenalidomide, and dexamethasone (D-VRd) in transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma (NDMM) patients, demonstrated higher rates of MRD negativity with DVRd, compared with VRd alone. Details of the screening process are presented in Figure 1. Prisma flow chart of included studies. Study characteristics In this meta-analysis, seven RCTs were included, conducted across Europe, the United States, Australia, Asia, and multinational settings spanning North and South America, Europe, and the Asia–Pacific region. The publication dates ranged from 2017 to 2025. A total 3,443 patients (1,759 in the daratumumab group and 1684 in the non-daratumumab group) were involved in these studies. The median age across studies ranged from approximately 59 to 76 years. Across all included studies, 55.4% of participants were male overall, with 54.9% in the daratumumab arm and 55.9% in the non-daratumumab arm. The baseline characteristics for the included studies are summarized in Tables 1 and 2. Table 1.Baseline characteristics of included studies (first 4 RCTs).Study characteristicStudy IDMoreau 2019Voorhees 2020Sonneveld P 2024Mateos 2017 Trial Name CASSIOPEIA GRIFFIN PERSEUS ALCYONE CountryEuropeUSAEuropeNorth and South America, Europe, Asia–Pacific regionSample size: Total (A vs B)1085 (543 vs 542)207 (104 vs 103)709 (355 vs 354)706 (350 vs 356)Median Age, in years (Range) A vs B59·0 (22–65) vs 58·0 (26–65)59 (29-70) vs 61 (40-70)61.0 (32–70) vs 59.0 (31–70)71.0 (40 - 93) vs 71.0 (50 - 91)Male (%) A vs B316 (58·2) vs 319 (58·9)58 (55.8) vs 60 (58.3)211 (59.4) vs 205 (57.9)160 (45.7) vs 167 (46.91)TEMM/TIEMMTEMMTEMMTEMMTIEMMRegimens (A vs B)D-VTD vs VTDD-RVd vs RVdD-VRD vs VRDD-VMP vs VMPDose of daratumumab in cycle 01 (mg)16mg/kg16mg/kg1800 mg16mg/kg Route of daratumumab: (SC, IV) IV IV SC IV ECOG Performance Score: 0, 1, 2.0D standard n (%)265 (49)39 (38.6)221 (62.3)78(22.3)Standard n (%)257 (47)40 (39.2)230 (65.0)99 (27.8)1D standard n (%)225 (41)51 (50.5)114 (32.1)182 (52.0)Standard n (%)230 (42)52 (51.0)108 (30.5)173 (48.6)≥2D standard n (%)53 (10)11 (10.9)20 (5.6)90 (25.7)Standard n (%)55 (10)10 (9.8)16 (4.5)84 (23.6)Not KnownD standard n (%)NRNRNRNRStandard n (%)NRNRNRNRType of measurable diseaseIgGD standard n (%)331 (61)55 (52.9)204 (57.5)143 (40.8)​Standard n (%)314 (58)52 (50.49)185 (52.3)140 (39.3)Non-IgGD standard n (%)212 (39)49 (47.1)151 (42.5)207 (59.1)Standard n (%)228 (42)51 (49.51)169 (47.7)216 (60.67)ISS Disease stageID standard n (%)204 (38)49 (47.1)186 (52.4)69 (19.7)Standard n (%)228 (42)50 (48.5)178 (50.4)67 (18.8)IID standard n (%)255 (47)40 (38.5)114 (32.1)139 (39.7)Standard n (%)233 (43)37 (35.9)125 (35.4)160 (44.9)IIID standard n (%)84 (15)14 (13.5)55 (15.5)142 (40.6)Standard n (%)81 (15)14 (13.6)50 (14.2)129 (36.2)Not KnownD standard n (%)NR1 (1.0)NRNRStandard n (%)NR2 (1.9)NRNRCytogenetics classificationStandardD standard n (%)460 (84.9)82 (83.7)264 (74.4)261 (83.1)Standard n (%)454 (84.1)83 (85.6)266 (75.1)257 (85.1)HighD standard n (%)82 (15.1)16 (16.3)76 (21.4)53 (16.9)Standard n (%)86 (15.9)14 (14.4)78 (22)45 ( (14.9)IndeterminateD standard n (%)NRNR15 (4.2)NRStandard n (%)NRNR10 (2.9)NRBaseline creatinine clearance (ml/min)D standard n (%)>90: 29 (5.3)>50: 95 (91.3)NR>60: 56 (16)<90: 16 (3)<50: 9 (8.7)NR<60: 32 (9.1)Standard n (%)>90: 47 (8.7)>50: 94 (91.3)NR>60: 80 (22.4)<90: 44 (8.1)<50: 9 (8.7)NR<60: 63 (17.7)DeathD standard n (%)14 (2.57)1 (1.01)34 (9.57)14 (4.0)Standard n (%)32 (5.9)0 (0)44 (12.4)16 (4.4)Median Time since initial diagnosis of MM, (months, range)D standard0·92 (0·2–9·4)0.7 (0-12)1.2 (0.0–46.5)0.8 (0.1 - 11.4)Standard0·92 (0·2–22·9)0.9 (0-61)1.1 (0.1–184.6)0.8 (0.1 - 25.3) Baseline characteristics of included studies (first 4 RCTs). Table 2.Baseline characteristics of included studies (last 3 RCTs).Study characteristicStudy IDMolle 2024Weijun Fu 2023Usmani 2025 Trial Name AMaRC 03-16 OCTANS CEPHEUS CountryAustraliaAsiaNorth America, EuropeSample size: Total (A vs B)121 (64 vs 57)220(146 vs 74)395 (197 vs 198)Median Age, in years (Range) A vs B75.9 (64 – 91) vs 75.4 (62 – 89)69.0 (58-81) vs 69.0 (57-84)70 (42–79) vs 70 (31–80)Male (%) A vs B49(76.6) vs 34(59.7)85(58.2) vs 46(62.1)87 (44.2) vs 111 (56.1)TEMM/TIEMMTIEMMTIEMMTIEMMRegimens (A vs B)VCDD vs VCDD-VMP vs VMPD-VRD vs VRDDose of daratumumab in cycle 01 (mg)16mg/kg16mg/kg1800 mg Route of daratumumab: (SC, IV) IV IV SC ECOG Performance Score: 0, 1, 2.0D standard n (%)26 (40.6)50 (34.2)71 (36)Standard n (%)26 (45.6)21 (28.4)84 (42.4)1D standard n (%)24 (37.5)71 (48.6)103 (52.3)Standard n (%)20 (35.1)40 (54.1)100 (50.5)≥2D standard n (%)13 (20.4)25 (17.1)23 (11.7)Standard n (%)10 (17.5)13 (17.6)14 (7.1)Not KnownD standard n (%)1 (1.6)NRNRStandard n (%)1 (1.8)NRNRType of measurable diseaseIgGD standard n (%)NR56 (38.4)89 (45.2)​Standard n (%)NR29 (39.2)76 (38.4)Non-IgGD standard n (%)NR90 (61.6)27 (13.7)Standard n (%)NR45 (60.8)31 (15.7)ISS Disease stageID standard n (%)8 (12.5)37 (25.3)68 (34.5)Standard n (%)6 (10.5)19 (25.7)68 (34.3)IID standard n (%)41 (64.1)37 (25.3)73 (37.1)Standard n (%)44 (77.2)32 (43.2)75 (37.9)IIID standard n (%)9 (14.1)41 (28.1)56 (28.4)Standard n (%)3 (5.3)23 (31.1)55 (27.8)Not KnownD standard n (%)6 (9.4)NRNRStandard n (%)4 (7.0)NRNRCytogenetics classificationStandardD standard n (%)42 (65.6)117 (80.7)149 (75.6)Standard n (%)43 (75.4)54 (73)149 (75.2)HighD standard n (%)12 (18.8)28 (19.3)25 (12.6)Standard n (%)7 (12.3)20 (33)27 (13.6)IndeterminateD standard n (%)10 (15.6)NRNRStandard n (%)7 (12.3)NRNRBaseline creatinine clearance (ml/min)D standard n (%)>60: 54 (84.4)>60: 83 (56.8)NR<60: 10 (15.6)<60: 63 (43.1)NRStandard n (%)>60: 43 (75.4)>60: 41 (55.4)NR<60: 14 (24.6)<60: 33 (44.6)NRDeathD standard n (%)5 (7.8)6 (4.1)NRStandard n (%)1 (1.7)4 (5.4)NRMedian Time since initial diagnosis of MM, (months, range)D standardNR0.66 (0.1-14.6)1.2 (0.4–5.8)StandardNR0.61 (0.1-2.1)1.3 (0.3–8.0)TEMM = Transplant Eligible Multiple Myeloma, TIEMM = Transplant Ineligible Multiple Myeloma, D-VTD = Daratumumab + Bortezomib+ Thalidomide + Dexamethasone, VTD = Bortezomib+ Thalidomide + Dexamethasone, D-RVd = Daratumumab + Lenalidomide+ Bortezomib +Dexamethasone, RVd = Lenalidomide + Bortezomib + dexamethasone, D-VMP = Daratumumab + Bortezomib + Melphalan + Prednisone.VMP = Bortezomib + Melphalan + Prednisone; VCDD= Daratumumab + Bortezomib + Cyclophosphamide + Dexamethasone, VCD = Bortezomib + Cyclophosphamide + Dexamethasone; IV = Intravenous; SC = Subcutaneous; ECOG = Eastern Cooperative Oncology Group; ISS = International Staging System; MM = Multiple Myeloma; NR = Not Reported. Baseline characteristics of included studies (last 3 RCTs). TEMM = Transplant Eligible Multiple Myeloma, TIEMM = Transplant Ineligible Multiple Myeloma, D-VTD = Daratumumab + Bortezomib+ Thalidomide + Dexamethasone, VTD = Bortezomib+ Thalidomide + Dexamethasone, D-RVd = Daratumumab + Lenalidomide+ Bortezomib +Dexamethasone, RVd = Lenalidomide + Bortezomib + dexamethasone, D-VMP = Daratumumab + Bortezomib + Melphalan + Prednisone. VMP = Bortezomib + Melphalan + Prednisone; VCDD= Daratumumab + Bortezomib + Cyclophosphamide + Dexamethasone, VCD = Bortezomib + Cyclophosphamide + Dexamethasone; IV = Intravenous; SC = Subcutaneous; ECOG = Eastern Cooperative Oncology Group; ISS = International Staging System; MM = Multiple Myeloma; NR = Not Reported. Bias assessment The Cochrane ROB 2.0 was used to evaluate the risk of bias in the studies that were included. Some bias concerns were observed in two of the included studies. These concerns were related to deviation from the intended intervention, outcome measurement, and reported result selection. The other four studies were judged to be at a low risk of bias. The summary graph for the quality assessment is in Supplementary Figure 1. Using the GRADE approach, the certainty of evidence ranged from high to moderate for most primary outcomes, while some secondary outcomes were graded as low certainty due to heterogeneity and imprecision (Table 3). Table 3.GRADE assessment.Patient or population: NDMMIntervention: DaraComparison: Non-daraOutcomesAnticipated absolute effects* (95% CI)Relative effect (95% CI)№ of participants (studies)Certainty of the evidence (GRADE)Risk with non-DARARisk with DARAMRD Overall302 per 1,000517 per 1,000(478 to 559)RR 1.71 (1.58 to 1.85)3443 (7 RCTs)⨁⨁⨁◯Moderate a OS200 per 1,000145 per 1,000 (114 to 186)HR 0.70 (0.54 to 0.92)2000 (6 RCTs)⨁⨁⨁⨁HighCR142 per 1,000159 per 1,000 (136 to 187)RR 1.12 (0.96 to 1.32)3432 (7 RCTs)⨁⨁◯◯Lowa,bVGPR333 per 1,000273 per 1,000 (200 to 372)RR 0.82 (0.60 to 1.12)3311 (6 RCTs)⨁⨁◯◯Lowa,bPFS0 per 1,000--per 1,000 (-- to --)HR 0.50 (0.43 to 0.58)3443 (7 RCTs)⨁⨁⨁⨁HighOR864 per 1,000933 per 1,000 (916 to 959)RR 1.08 (1.06 to 1.11)3432 (7 RCTs)⨁⨁⨁◯Moderate a sCR249 per 1,000394 per 1,000 (339 to 461)RR 1.58 (1.36 to 1.85)3432 (7 RCTs)⨁⨁⨁⨁HighCR or better402 per 1,000575 per 1,000 (499 to 664)RR 1.43 (1.24 to 1.65)3311 (6 RCTs)⨁⨁⨁◯Moderate a VGPR or better719 per 1,000878 per 1,000 (784 to 971)RR 1.22 (1.09 to 1.35)3432 (7 RCTs)⨁⨁⨁◯Moderate a CI: confidence interval; HR: hazard ratio; RR: risk ratio.*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).Explanations.aHigh I2 more than 50%.b95% crossess 0. GRADE assessment. CI: confidence interval; HR: hazard ratio; RR: risk ratio. *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). Explanations. aHigh I2 more than 50%. b95% crossess 0. Meta-analysis of primary efficacy-related outcomes 1: Progression free survival (PFS) Seven studies, involving a total of 3,443 patients (1759 DARA vs 1684 non-DARA), showed a significantly high progression-free survival (PFS) for the DARA group compared to the non-DARA group (HR 0.50, 95%CI: 0.43- 0.58, p < 0.00001, I2= 0%) (Figure 2). Forest plot of progression-free survival (PFS). The funnel plot demonstrated a symmetric distribution of studies around the pooled effect estimate, suggesting no significant evidence of publication bias (Supplementary Figure 8a). Subgroup analysis 1) Subgroup analysis based on cytogenetic risk showed statistically significant high PFS both for standard cytogenetic risk (HR 0.45, 95%CI 0.38-0.55, P<0.00001), as well as high cytogenetic risk (HR 0.67, 95%CI: 0.51-0.89, P= 0.006) (Supplemental Figure 9a). 1) Subgroup analysis based on cytogenetic risk showed statistically significant high PFS both for standard cytogenetic risk (HR 0.45, 95%CI 0.38-0.55, P<0.00001), as well as high cytogenetic risk (HR 0.67, 95%CI: 0.51-0.89, P= 0.006) (Supplemental Figure 9a). 2) Subgroup analysis based on transplant eligibility showed statistically significant benefits for both TE and TIE subgroup. TEMM (HR 0.44, 95%CI 0.35-0.56; P < 0.00001) and TIE-MM (HR 0.54, 95%CI 0.45-0.65; P < 0.00001) (Supplemental Figure 9b). 2) Subgroup analysis based on transplant eligibility showed statistically significant benefits for both TE and TIE subgroup. TEMM (HR 0.44, 95%CI 0.35-0.56; P < 0.00001) and TIE-MM (HR 0.54, 95%CI 0.45-0.65; P < 0.00001) (Supplemental Figure 9b). 2: MRD negativity This outcome was reported by 7 RCTs with 3443 patients (1759 Dara vs 1684 non-Dara). The analysis showed statistically significant MRD negativity with daratumumab based quadruplet therapy compared to non-Dara triplet arm (RR 1.99, 95%CI 1.59-2.50, P<0.00001) (Figure 3). Forest Plot of MRD negativity. The funnel plot displayed a symmetric distribution of studies around the pooled effect estimate, indicating no significant evidence of publication bias (Supplementary Figure 8b). Subgroup analysis 1) Subgroup analysis based on cytogenetic risk showed that there was significantly high MRD negativity in standard risk group (RR 1.76, 95%CI 1.42-2.18, P<0.00001), compared to non-significant increase MRD negativity in the high-risk group (RR 1.23, 95%CI 0.87-1.73, P=0.24) (Supplementary Figure 9c). 1) Subgroup analysis based on cytogenetic risk showed that there was significantly high MRD negativity in standard risk group (RR 1.76, 95%CI 1.42-2.18, P<0.00001), compared to non-significant increase MRD negativity in the high-risk group (RR 1.23, 95%CI 0.87-1.73, P=0.24) (Supplementary Figure 9c). 2) Subgroup analysis based on transplant eligibility showed that MRD negativity was significantly high in both TE (RR 1.62, 95%CI: 1.37-1.92, P <0.00001), and TIEMM (RR 2.79, 95% CI: 1.58-4.93, P =0.0004) (Supplemental Figure 9d). 2) Subgroup analysis based on transplant eligibility showed that MRD negativity was significantly high in both TE (RR 1.62, 95%CI: 1.37-1.92, P <0.00001), and TIEMM (RR 2.79, 95% CI: 1.58-4.93, P =0.0004) (Supplemental Figure 9d). Secondary efficacy related outcomes 1: Stringent complete response (sCR) A total of seven studies encompassed a total of 3,443 patients (1754 DARA vs 1678 non-DARA). The findings demonstrated a statistically significant higher sCR rate in the DARA group compared with the non-DARA group. (RR 1.58, 95%CI: 1.36-1.85, p < 0.00001, I2 = 47%) (Figure 4). Forest Plot of sCR. The funnel plot showed a symmetric distribution of studies around the pooled effect estimate, indicating no apparent publication bias (Supplementary Figure 8c). Subgroup analysis of sCR 1) Subgroup analysis was conducted based on cytogenetic risk. The results showed that high cytogenetic risk has comparable sCR across both arm (RR 0.82, p=0.45), compared to the standard cytogenetic risk group, which shows a significant increase in sCR (RR 1.52, p<0.0001) (Supplemental Figure 9e). 1) Subgroup analysis was conducted based on cytogenetic risk. The results showed that high cytogenetic risk has comparable sCR across both arm (RR 0.82, p=0.45), compared to the standard cytogenetic risk group, which shows a significant increase in sCR (RR 1.52, p<0.0001) (Supplemental Figure 9e). 2) Subgroup analysis based on transplant eligibility showed statistically significant higher sCR for both TE and TIE subgroup. TE-MM (RR 1.50 CI 1.34-1.67; P < 0.00001, i2= 0%) and TIE-MM (RR 2.18, 95%CI 1.26-3.77; P= 0.005, i2= 72%) (Supplemental Figure 9f). 2) Subgroup analysis based on transplant eligibility showed statistically significant higher sCR for both TE and TIE subgroup. TE-MM (RR 1.50 CI 1.34-1.67; P < 0.00001, i2= 0%) and TIE-MM (RR 2.18, 95%CI 1.26-3.77; P= 0.005, i2= 72%) (Supplemental Figure 9f). 2: Overall survival This outcome was reported by 7 RCTs. Daratumumab based quadruplet therapy was associated with a significantly improved overall survival compared with non-daratumumab-based triplet therapy (HR 0.71, 95%CI 0.55-0.90, P= 0.005) (Supplementary Figure 2). The funnel plot demonstrated a symmetric distribution of studies around the pooled effect estimate, suggesting no significant evidence of publication bias (Supplementary Figure 8d). 3: Complete response or better This outcome was reported by 6 studies 3311 (1690 Dara vs 1621 non-DARA). The analysis showed statistically significant complete response or better in Daratumumab based quadruplet therapy versus non-Dara based triplet therapy (RR1.43, 95%CI 1.24-1.65, P<0.00001) (Supplemental Figure 3). The funnel plot demonstrated a symmetric distribution of studies around the pooled effect estimate, suggesting no significant evidence of publication bias (Supplementary Figure 8e). Subgroup analysis based on transplant eligibility showed higher CR or better in both TE (RR 1.32, 95%CI 1.15-1.51, P <0.00001), and TIE (RR 1.66, 95%CI 1.20-2.31) (Supplementary Figure 9g). 4: VGPR or better This outcome was reported by 7 studies 3432 patients (1754 DARA vs 1678 non-DARA). The analysis showed statistically significant higher VGPR or better in Dara based quadruplet therapy vs non-Dara triplet therapy (RR 1.22, 95%CI 1.09-1.35, P=0.000) (Supplemental Figure 4). The funnel plot demonstrated symmetry around the pooled effect estimate, providing no evidence of significant publication bias (Supplementary Figure 8f). 5: Overall response This outcome being reported by 7 studies in 3432 patients (1754 Dara vs 1678 non-Dara). The forest plot showed that OR is significantly higher in quadruplet therapy compared to non-Dara based triplet therapy (RR 1.09, 95%CI 1.03-1.15, P=0.002) (Supplemental Figure 5). The funnel plot showed a symmetrical distribution of studies around the pooled effect estimate, indicating no evidence of publication bias (Supplementary Figure 8g). 6: Complete response This outcome was extracted from 7 studies with 3432 patients (1754 Dara vs 1678 non-Dara). The analysis revealed no significant difference in complete response between Dara based quadruplet therapy and non-Dara based triplet therapy (RR 1.16, 95%CI: 0.85-1.59, P= 0.35) (Supplemental Figure 6). The funnel plot demonstrated a symmetric distribution of studies around the pooled effect estimate, suggesting no significant evidence of publication bias (Supplementary Figure 8h). 7: VGPR This outcome was reported by 6 studies including 3311 patients (1690 Dara vs 1621 non-Dara). The forest plot showed comparable VGPR between two arms (RR 0.82, 95%CI: 0.60-1.12, p= 0.20) (Supplemental Figure 7). The funnel plot demonstrated a symmetric distribution of studies around the pooled effect estimate, suggesting no significant evidence of publication bias (Supplementary Figure 8I). Adverse effects a) hematological Hematological adverse events were more frequent with daratumumab-based regimens. Neutropenia showed the most pronounced increase, both for any grade (56.2% vs 40.3%) and grade ≥3 events (41.2% vs 31.7%). Similarly, thrombocytopenia was higher in the daratumumab arm (40.7% vs 32.5% for any grade; 25.1% vs 19.5% for grade ≥3). Lymphopenia also occurred more commonly with daratumumab, particularly for severe events (18.6% vs 12.1%). In contrast, anemia rates were comparable between groups for both any grade and grade ≥3 events, suggesting no significant additional risk attributable to daratumumab (Table 4). Table 4.Hematological and non-hematological adverse events.EventsAny gradeGrade 3 or moreDara n (%)Non-DARA n (%)Dara n (%)Non-DARA n (%)Hematological Adverse EventsNeutropenia842 (56.2%)647 (40.3%)689 (41.2%)509 (31.7%)Thrombocytopenia707 (40.7%)541 (32.5%)419 (25.1%)313 (19.5%)Anemia385 (32.1%)360 (32.0%)146 (12.8%)140 (13.1%)Lymphopenia230 (22.1%)163 (16.9%)182 (18.6%)110 (12.1%)Non-Hematological Adverse EventsUpper Respiratory Infection398 (33.1%)262 (23.3%)22 (1.8%)15 (1.3%)Constipation578 (41.5%)531 (40.5%)21 (1.5%)13 (1.0%)Peripheral sensory neuropathy787 (45.0%)845 (49.7%)93 (5.7%)102 (6.3%)Fatigue228 (26.6%)227 (26.4%)34 (4.0%)40 (4.7%)Infusion-related reaction312 (33.0%)Not applicable32 (3.4%)Not applicablePyrexia413 (31.5%)309 (25.2%)27 (2.1%)25 (2.1%)Peripheral edema365 (28.0%)342 (27.4%)13 (1.0%)11 (0.9%)Nausea347 (26.4%)301 (24.3%)25 (1.9%)19 (1.5%)Cough192 (22.3%)118 (15.3%)2 (0.3%)2 (0.3%)Asthenia316 (30.8%)284 (29.3%)26 (2.5%)20 (2.1%)Back pain173 (26.1%)143 (22.3%)9 (1.4%)11 (1.7%)Second primary cancer62 (5.7%)55 (5.2%)0 (0.0%)0 (0.0%) Hematological and non-hematological adverse events. b) non-hematological adverse events Among non-hematological adverse events, infection-related outcomes were notably increased with daratumumab, including upper respiratory tract infections (33.1% vs 23.3%) and pyrexia (31.5% vs 25.2%), along with a higher incidence of cough. Infusion-related reactions were observed exclusively in the daratumumab arm, as expected (these reactions were particularly in RCTs where intravenous form of daratumumab was used, and was significantly less in studies where subcutaneous route was used). Gastrointestinal and general symptoms such as constipation, nausea, fatigue, asthenia, and peripheral edema were largely comparable between groups. Peripheral sensory neuropathy appeared slightly lower with daratumumab, likely reflecting differences in backbone regimens. Rates of serious events (grade ≥3) remained low across most non-hematological outcomes, with minimal differences between treatment arms (Table 4). Discussion This meta-analysis indicates that daratumumab (DARA) -based quadruplet regimens significantly improve progression-free survival (PFS) (HR 0.50) and the rate of stringent complete response (sCR) (RR 1.58) in patients with multiple myeloma (MM), regardless of transplant eligibility. Minimal residual disease (MRD) negativity was also markedly higher with these regimens (RR 1.99). Additional efficacy benefits were observed for overall survival (HR 0.71), overall response rate (RR 1.09), and VGPR or better (RR 1.22). However, these improvements in clinical outcomes were associated with an increased risk of treatment-emergent adverse events, particularly neutropenia, thrombocytopenia, and infection-related complications. The mechanism underlying the therapeutic effects of daratumumab (DARA) involves targeting CD38 expressed on myeloma cells, thereby inducing apoptosis through complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).20–23 In addition, DARA modulates the immune microenvironment by depleting regulatory T cells and myeloid-derived suppressor cells. 24 Both intravenous and subcutaneous formulations of DARA are approved for the treatment of MM.25–27 Regarding progression-free survival, our pooled analysis showed a marked improvement with daratumumab-based quadruplet therapy (HR 0.50), in line with recent meta-analyses.10,28,29 Subgroup analyses based on cytogenetic risk demonstrated that this benefit extended to both standard-risk (HR 0.45) and high-risk (HR 0.67) patients, although it was less pronounced in the latter group. These findings suggest that while quadruplet therapy enhances disease control across different risk categories, it does not fully overcome the unfavorable prognosis associated with high-risk cytogenetic features. This observation is consistent with data from recent trials, including PERSEUS and CEPHEUS, where high-risk patients experienced clinical benefit but continued to have comparatively poorer outcomes than standard-risk individuals.17,19 Minimal residual disease (MRD) negativity was significantly enhanced with daratumumab-based quadruplet therapy (RR 1.99), supporting its effectiveness in achieving deeper treatment responses. However, subgroup analysis revealed variability according to cytogenetic risk. MRD negativity was significantly improved among standard-risk patients (RR 1.76), whereas the increase did not reach statistical significance in high-risk patients (RR 1.23). This finding highlights a key limitation of existing therapeutic approaches, as patients with high-risk cytogenetic features appear less likely to attain sustained MRD negativity. Furthermore, emerging data indicate that MRD negativity may not yield equivalent prognostic value in high-risk populations compared with standard-risk groups, potentially reflecting more aggressive disease biology and greater clonal heterogeneity.30,31 Collectively, these results highlight the necessity for risk-adapted treatment strategies and the development of novel therapeutic options for this subgroup. Our analysis demonstrated a significant improvement in stringent complete response (sCR) with daratumumab-based quadruplet therapy (RR 1.58), consistent with prior meta-analyses and recent studies evaluating intensified induction regimens.5,9,10 Subgroup analysis further indicated that this benefit was predominantly observed in standard-risk patients (RR 1.52), while no statistically significant improvement was seen in the high-risk subgroup. This pattern highlights the persistent challenge of achieving deep responses in biologically aggressive disease. Collectively, these findings emphasize the importance of individualized treatment strategies, suggesting that patients with high-risk features may require additional therapeutic intensification or the incorporation of novel agents beyond current quadruplet regimens.32,33 The observed improvement in overall survival (HR 0.71) further supports the clinical benefit of daratumumab-based quadruplet therapy. Although earlier studies were constrained by immature survival data, more recent trials and updated analyses have begun to demonstrate a clear survival advantage associated with daratumumab-containing regimens.19,28 This outcome likely reflects the cumulative effect of achieving deeper responses and enhanced disease control, thereby supporting the incorporation of quadruplet therapy as a frontline standard of care in eligible patients. These findings are also consistent with the latest European Hematology Association–European Myeloma Network (EHA–EMN) recommendations, which place anti-CD38 monoclonal antibody–based quadruplet regimens among the preferred initial treatment options for newly diagnosed multiple myeloma. Our results provide pooled randomized evidence supporting these recommendations, while also showing that the magnitude of benefit may remain lower in patients with high-risk cytogenetic features. 34 Secondary efficacy outcomes also favored daratumumab-based quadruplet therapy, demonstrating significant improvements in complete response or better (RR 1.43), very good partial response (VGPR) or better (RR 1.22), and overall response rate (RR 1.09), in line with findings from previous studies.35–37 However, individual endpoints such as complete response and VGPR alone did not reach statistical significance, suggesting that the primary benefit of this approach lies in achieving deeper and more sustained responses rather than simply increasing initial response rates. The safety analysis indicated an increased incidence of hematological toxicities, particularly neutropenia and thrombocytopenia, as well as a higher rate of infection-related adverse events, including upper respiratory tract infections and pneumonia. These findings are consistent with prior meta-analyses.37,38 Nevertheless, most non-hematological adverse events were comparable between treatment groups, and the occurrence of serious toxicities remained relatively low, supporting an overall manageable safety profile. Importantly, the increased frequency of certain adverse events did not result in higher rates of treatment discontinuation, indicating that these toxicities are largely manageable and exert minimal impact on overall treatment outcomes. Overall, these findings favor daratumumab-based quadruplet therapy as a frontline treatment approach in newly diagnosed multiple myeloma, particularly among patients with standard-risk disease. In contrast, the more limited benefit seen in high-risk cytogenetic subgroups points to a continuing gap in treatment efficacy, highlighting the need for tailored therapeutic strategies and the development of novel approaches for this population. Although this analysis specifically focused on daratumumab-based quadruplet regimens, the findings should be interpreted in the broader context of anti-CD38–directed therapies. Isatuximab-based combinations have shown comparable efficacy, with significant progression-free survival benefits reported in ICARIA-MM (HR 0.60, 95% CI 0.44–0.81) and IKEMA (HR 0.53, 95% CI 0.32–0.89), suggesting a possible class effect.39,40 Likewise, our recent meta-analysis (Osama et al.) confirmed improved survival and response outcomes associated with anti-CD38–based therapies. 41 Moreover, daratumumab-based regimens incorporating carfilzomib (Dara-KRd) have achieved high rates of MRD negativity (>60%) and have been associated with durable responses. 42 Limitations This meta-analysis has several limitations. First, it included only randomized controlled trials, excluding cohort studies that may provide additional insights and reflect real-world evidence. In addition, the analysis did not account for the impact of maintenance therapy or variations in regimens combined with daratumumab. Reporting of disease staging was also inconsistent, with only one study providing Revised International Staging System (R-ISS) data, while others reported the International Staging System (ISS) alone, and none included SLiM-CRAB criteria. Consequently, subgroup analyses based on these classifications could not be performed. Addressing these limitations in future studies may offer a more comprehensive understanding of the impact of daratumumab in patients with multiple myeloma. Clinical implications This meta-analysis demonstrates that daratumumab-based quadruplet therapy is associated with improved survival, enhanced response rates, and higher rates of MRD negativity in newly diagnosed multiple myeloma. From a clinical standpoint, these results support its adoption as a first-line induction approach in eligible patients. Moving forward, these findings may inform more personalized treatment strategies, shape decisions regarding sequencing and maintenance, and further position daratumumab-based quadruplet regimens as a key standard for optimizing long-term outcomes in multiple myeloma. Conclusion In conclusion, daratumumab-based regimens significantly improve key efficacy outcomes, including progression-free survival (PFS), and MRD negativity in patients with multiple myeloma, particularly among those with standard-risk disease and earlier-stage presentation. Our analysis, restricted to randomized controlled trials, also identified an increased risk of certain infections associated with these regimens, highlighting the importance of vigilant monitoring and prophylaxis for their prevention. These findings support the need for individualized treatment approaches, taking into account patient-specific factors such as cytogenetic risk, and disease characteristics to optimize clinical outcomes. Supplemental material Supplemental material - Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials Supplemental material for Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials by Muhammad Osama, Muhammad Haris Khan, Ammara Tahir, Amna Hussain, Ahmad Iftikhar, Aizaz Ali, Safeena Khan, Malak Bilal Hassan, Intikhab Alam, Zeeshan Khan, Abdullah Afridi, Mohammad Ebad Ur Rehman, Amna Gul, Pawan Kumar Thada in Therapeutic Advances in Hematology Acknowledgements The abstract for this meta-analysis has already been published in the “Blood” journal of ASH. Author contributions: Muhammad Osama Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft. Muhammad Haris Khan, Ahmad Iftikhar, and Ammara Tahir were involved in screening studies, data extraction, formal analysis, and quality assessment. Amna Hussain, Ahmad Iftikhar, Safeena Khan, and Aizaz Ali assisted in the data curation, formal analysis, and investigation, and critically revised the manuscript for important intellectual content. Malak Bilal Hassan, Ahmad Iftikhar, Zeeshan Khan, and Intikhab Alam evaluated the risk of bias and ensured adherence to PRISMA guidelines. Mohammad Ebad Ur Rehman, Amna Gul and Abdullah Afridi contributed to subgroup analyses and graphical presentations. reviewed the methodology and provided significant input on the results interpretation. Pawan Kumar Thada, as the corresponding author, performed formal analysis, manuscript writing, provided overall guidance, reviewed the manuscript rigorously, and ensured its readiness for submission. Funding: The authors received no financial support for the research, authorship, and/or publication of this article. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Trial registration: This meta-analysis is registered in PROSPERO (CRD42024584896). Supplemental material: Supplemental material for this article is available online. ORCID iDs Muhammad Osama https://orcid.org/0000-0003-0197-4264 Zeeshan Khan https://orcid.org/0009-0006-4563-7760 Ethical considerations The study did not require ethical approval, and the authors have nothing to report. (Already available data used). Data Availability Statement The datasets obtained and analyzed in the current study are available from the corresponding author upon reasonable request.* References Associated Data Supplementary Materials Supplemental material - Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials Supplemental material for Efficacy and safety of daratumumab-based quadruplet therapy vs non-daratumumab-based triplet therapy in newly diagnosed multiple myeloma patients: A GRADE assessed systematic review and meta-analysis of randomized controlled trials by Muhammad Osama, Muhammad Haris Khan, Ammara Tahir, Amna Hussain, Ahmad Iftikhar, Aizaz Ali, Safeena Khan, Malak Bilal Hassan, Intikhab Alam, Zeeshan Khan, Abdullah Afridi, Mohammad Ebad Ur Rehman, Amna Gul, Pawan Kumar Thada in Therapeutic Advances in Hematology Data Availability Statement The datasets obtained and analyzed in the current study are available from the corresponding author upon reasonable request.*